Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report, dated September 19, 2025, covers the month of September 2025 for Purple Biotech Ltd., a foreign private issuer headquartered in Rehovot, Israel. The filing primarily addresses corporate actions regarding equity financing programs rather than operational financial results.
Key Financial Metrics and Capital Activities
- New ATM Program: Entered into an "At The Market Offering Agreement" with H.C. Wainwright & Co., LLC on September 19, 2025.
- Offering Capacity: The Company may offer and sell American Depositary Shares (ADSs) with an aggregate offering price of up to $2,300,000 under the new agreement.
- Terminated Program Proceeds: Under the terminated Jefferies ATM Program (active since June 2021), the Company sold 983,317 ADSs for aggregate gross proceeds of $7,729,691.
- Average Sale Price: The average price per ADS under the terminated Jefferies program was $7.86.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change is the transition of the Company's equity distribution agent. Effective September 18, 2025, the Company terminated its Open Market Sale Agreement with Jefferies LLC. Concurrently, on September 19, 2025, the Company initiated a new ATM agreement with H.C. Wainwright & Co., LLC to continue its ability to sell ADSs in the open market.
Outlook, Risks, and Management Commentary
The filing indicates the Company's intent to raise capital through the new ATM facility up to the $2.3 million limit. No specific guidance on future revenue, clinical milestones, or operational outlook is provided in this document. The filing incorporates by reference various prior registration statements (Forms S-8 and F-3) but does not detail specific risks or contingencies within the body of this report.
Investor Verification Checklist
- Verify the current cash position and burn rate to assess the necessity of the new $2.3 million ATM facility.
- Review the prospectus supplement dated September 19, 2025, for specific terms of the Wainwright agreement.
- Confirm the dilution impact of the 983,317 ADSs sold under the previous Jefferies program.
- Check recent trading volumes and price trends for ADSs to gauge market reception of the new ATM program.